Meridian Clinical Research, LLC

Endwell, New York 13760

0 studies enrolling now · 11 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, COVID-19, Clostridium Difficile Infection, Influenza, Human, Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention, Lower Respiratory Tract Disease, Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19, Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol, Pneumococcal Disease, Respiratory Syncytial Virus Infections, Respiratory Syncytial Viruses, SARS-CoV-2 Infection

Studies at this site

• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Completed
• Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age — Completed
• A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older — Completed
• EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 — Completed
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults — Completed
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants — Completed
• MVA-BN-RSV Vaccine Trial — Stopped early
• Clostridium Difficile Vaccine Efficacy Trial — Completed
• Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 — Completed
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — Completed